Surgery plus TKIs therapy for gastrointestinal stromal tumors

Yang, Tiequan; Gao, Boyang; Zheng, Keji

doi:10.2478/ahem-2024-0004

Figures & Tables

Flow chart of literature selection process

Meta-analysis of 3-year PFS between surgery plus TKIs group and TKIs alone group. A forest plot displays individual study results (squares) along with their confidence intervals (horizontal lines). The size of the square represents the weight of the study. The pooled odds ratio is represented by a diamond, with the diamond’s width indicating the 95% confidence interval for the pooled odds ratio

Begg’s funnel plot for visual assessment of no publication bias for 3-year PFS

Egger’s publication bias plot showed no publication bias for 3-year PFS

Meta-analysis of 3-year OS between surgery plus TKIs group and TKIs alone group. A forest plot displays individual study results (squares) along with their confidence intervals (horizontal lines). The size of the square represents the weight of the study. The pooled odds ratio is represented by a diamond, with the diamond’s width indicating the 95% confidence interval for the pooled odds ratio

Meta-analysis of 5-year OS between surgery plus TKIs group and TKIs alone group. A forest plot displays individual study results (squares) along with their confidence intervals (horizontal lines). The size of the square represents the weight of the study. The pooled odds ratio is represented by a diamond, with the diamond’s width indicating the 95% confidence interval for the pooled odds ratio

Meta-analysis of 5-year OS between surgery plus TKIs group and TKIs alone group for GLM. A forest plot displays individual study results (squares) along with their confidence intervals (horizontal lines). The size of the square represents the weight of the study. The pooled odds ratio is represented by a diamond, with the diamond’s width indicating the 95% confidence interval for the pooled odds ratio

Characteristics of studies included in meta-analysis of role of surgery for patients with recurrent or metastatic gastrointestinal stromal tumors

Author, Year	Country	No. of patients	Sex(male/female)	Mean age (year)	Mean Tumor size (cm)	Classification of recurrent or metastatic GISTs	Type of TKIs	Timing of TKIs	Surgical management	Follow-up (median, range)	Study design
Chang SC 2015[18]	China	182	S:44/32	S:55.89	----	metastatic or recurrent GISTs	imatinib	Preop + Postop	R0 30 R1 9 R2 37	----	Retrospective
Chang SC 2015[18]	China	182	NS:66/40	NS:58.42	----			Preop + Postop	R0 30 R1 9 R2 37	----	Retrospective
Zaydfudim V 2015[9]	USA	87	S:31/23	S:61	S:9 NS:9	metastatic or recurrent GISTs	Imatinib or sunitinib	Preop + Postop	R0 32 R1 3 R2 19	----	Retrospective
Zaydfudim V 2015[9]	USA	87	NS:17/16	NS:60	S:9 NS:9			Preop + Postop	R0 32 R1 3 R2 19	----	Retrospective
Sato S 2016 [19]	Japan	93	S:28/22	S:60	S:7.5	metastatic or recurrent GISTs	Imatinib	Postop only	R0 29 R1 5 R2 13	75.2	Retrospective
Sato S 2016 [19]	Japan	93	NS:28/15	NS:69.7	NS:8			Postop only	R0 29 R1 5 R2 13	75.2	Retrospective
Shi YN 2017 [20]	China	130	90/54	56	----	metastatic GISTs	Imatinib then sunitinib	Postop only	R0 23 R1/R2 9	48.2	Retrospective
Xiao B 2018 [21]	China	102	S:11/10	52	4.4	metastatic GISTs	Imatinib then sunitinib	Postop only	R0 15 R1/R2 6	----	Retrospective
Xiao B 2018 [21]	China	102	NS:60/21	52	4.4			Postop only	R0 15 R1/R2 6	----	Retrospective
Xia L 2010 [22]	China	39	S:10/9	53	S: 8.9	metastatic GISTs	Imatinib	Preop + Postop	----	36	Retrospective
Xia L 2010 [22]	China	39	NS:11/9	55	N:9.3			Preop + Postop	----	36	Retrospective
Bauer S 2005[8]	USA	90	S:6/6	S:57	-----	Metastatic GISTs	Imatinib	Preop + Postop	R0 11 R1/R2 1	----	Retrospective
Bauer S 2005[8]	USA	90	NS:45/33	NS:62	-----			Preop + Postop	R0 11 R1/R2 1	----	Retrospective
Xue A 2022 [23]	China	119	S:34/28	56	4	metastatic GISTs	imatinib	Preop + Postop	R0 44 R1 16 R2 2	56	Retrospective
Xue A 2022 [23]	China	119	NS:37/20	56	4			Preop + Postop	R0 44 R1 16 R2 2	56	Retrospective

Newcastle-Ottawa Scale Assessment of enrolled studies

Author, Year	Selection (0–4)	Comparability (0–2)	Outcome (0–3)	Quality score
Chang SC 2015[18]	4	1	3	8
Zaydfudim V 2015[9]	4	1	2	7
Sato S 2016 [19]	4	1	2	7
Shi YN 2017 [20]	4	1	2	7
Xiao B 2018 [21]	4	1	3	8
Xia L 2010 [22]	4	1	2	7
Bauer S 2005[8]	4	1	3	8
Xue A 2022 [23]	4	1	3	8

Surgery plus TKIs therapy for gastrointestinal stromal tumors

Figures & Tables

Figure 1.

Figure 2A.

Figure 2B.

Figure 2C.

Figure 3.

Figure 4.

Figure 5.

Characteristics of studies included in meta-analysis of role of surgery for patients with recurrent or metastatic gastrointestinal stromal tumors

Newcastle-Ottawa Scale Assessment of enrolled studies

Paradigm

My account